# Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

> **NCT03640481** · PHASE2 · TERMINATED · sponsor: **Kadmon, a Sanofi Company** · enrollment: 159 (actual)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **DRUG:** Belumosudil (KD025)

## Key facts

- **NCT ID:** NCT03640481
- **Lead sponsor:** Kadmon, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-11
- **Primary completion:** 2023-12-11
- **Final completion:** 2023-12-11
- **Target enrollment:** 159 (ACTUAL)
- **Why stopped:** The sponsor has decided to prematurely terminate the study due to the challenges encountered in recruiting adolescent participants. This decision was made without any safety concerns.
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03640481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03640481, "Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03640481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*